Thus we next determined whether [ruxolitinib + MMF] treatment altered the production of reactive oxygen species (ROS) in tumor cells and whether the over-expression of SOD2 or TRX could suppress drug combination toxicity. The gene discussed is TXN; the disease is neoplasm.